The UCL and Ludwig Institute-linked cancer immunotherapy developer has raised more than $200m in funding and has filed to raise up to $100m.

iTeos Therapeutics, a US-based immuno-oncology drug spinout of Universit√© catholique de Louvain (UCL) and Ludwig Institute for Cancer Research, filed for a $100m initial public offering on Wednesday. Founded in 2011, iTeos is working on cancer immunotherapies and plans to channel the IPO proceeds into the clinical development of a small molecule drug candidate called…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.